Intelligent Bio Solutions INC 8-K filings

Intelligent Bio Solutions Inc. released a presentation on April 9, 2024, detailing the company's business and operations.

Intelligent Bio Solutions Inc. has successfully completed a $10.1 million private placement to institutional and accredited investors.

Intelligent Bio Solutions Inc. has entered into agreements with C2C Advisors Inc. and ClearThink Capital LLC for advisory and investor relations services, involving cash payments and stock grants.

Intelligent Bio Solutions has partnered with Cliantha Research to conduct a pharmacokinetic study as part of its FDA 510(k) clinical study plan for its fingerprint drug screening system.

Intelligent Bio Solutions Inc. has successfully regained compliance with Nasdaq listing requirements regarding minimum share price and stockholders' equity.

Intelligent Bio Solutions Inc. reported a 114% year-over-year revenue increase for the fiscal second quarter and a 337% increase for the six-month period ending December 31, 2023, driven by product sales and market expansion.

Intelligent Bio Solutions Inc. has generated approximately $1.77 million in gross proceeds by inducing the exercise of existing warrants and issuing new replacement warrants.

Intelligent Bio Solutions Inc. announced a 114% year-over-year revenue increase for the second fiscal quarter and a 337% increase for the six months ended December 31, 2023.

Intelligent Bio Solutions' fingerprint drug screening system will be deployed across 25 UK sites of James Jones & Sons, a leading timber processor, to support their new substance misuse policy.

Intelligent Bio Solutions implemented a 1-for-12 reverse stock split to increase its share price and comply with Nasdaq's minimum listing requirements.